Search results
Results from the WOW.Com Content Network
The 2024 update of the Global Strategy for Asthma Management and Prevention incorporates new scientific information about asthma based on a review of recent scientific literature by an international panel of experts on the GINA Science Committee.
GUIDELINES & REPORTS. The GINA global strategy for asthma management and prevention is presented in its strategy documents, which are freely available on the GINA Website. The GINA Scientific Committee prepares updates to these documents each year, which are made available on the GINA Website as they are completed.
Download our 2016 Pocket Guide for Asthma Management and Prevention. This guide is in PDF format and helpful for all users.
The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances ( e.g. medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes.
The GINA Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention. This article summarizes key recommendations from GINA 2021, and the evidence underpinning the new changes. …
The GINA 2024 asthma update includes new guidance on medications, monitoring, treatment goals, remission, cough variant asthma, children, and more.
The 2019 Global Initiative for Asthma (GINA) guidelines recommend that all asthma patients be treated with inhaled corticosteroids taken daily or as needed; this improves symptoms and outcomes, even in those with mild disease.
Pocket Guide for asthma management and prevention for adults and children older than 5 years (updated 2020). Summary for primary health care providers, to be used in conjunction with the main GINA report. Difficult-to-treat and severe asthma in adolescent and adult patients. Diagnosis and Management.
The latest update to the Global Initiative for Asthma (GINA) guidelines includes significant changes to treatment recommendations, especially a recommendation against using a short-acting beta2...
This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting β 2-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS ...